Skip to main content
WELL $235.52 +0.46%
WELL logo

WELL · Welltower Inc.

Track WELL — free
$235.52 +1.08 (+0.46%) At close · Aug 14
Market Cap
$166.26B
Shares
705.91M
All earnings calls

Earnings call · FY2026 Q1

Welltower Inc. Q4 FY2025 Earnings Call

Welltower Inc. Q4 FY2025 Earnings Call

Concluded Apr 29, 2026 Audio replay
Apr 29, 2026 1:11:09 59 turns
Period
FY2026 Q1
Runtime
1:11:09
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Welltower delivered a transformational 2025 with 36% revenue growth, 32% EBITDA growth, and 22% FFO per share growth, alongside $11 billion of net investment activity funded largely by the $7.2 billion Outpatient Medical portfolio sale. Q4 same-store NOI grew 15.0% (SHO portfolio +20.4%), and the company already has $5.7 billion of further acquisitions closed or under contract early in 2026.

Welltower Business System and tech platform 18 Operating partner ecosystem and product optimization 15 Portfolio transformation and capital rotation 8 Private funds management business 7 Acquisition pipeline and deal discipline 5 Demand and supply outlook for senior housing 4

Management tone

Confident

Net tone +82 · low hedging

Grounding quotes
  • “2025 not only marked the ten-year anniversary of the refounding of our company by the current management, but also proved to be the most pivotal year in the company's history.”
  • “We launched our private funds management business, overhauled our internal and external incentive structure, made substantial progress on Welltower Business System initiatives, and created our tech quad to take our technology journey to the next level.”
  • “we ended the strongest year in our company's history on a high note, reporting the thirteenth consecutive quarter in which same-store operating net operating income growth exceeded 20%”
  • “$5.7 billion of acquisitions and with $2.5 billion of new deals completed or under contract in just the first six weeks of the year, and a robust pipeline that can be described as granular, visible, and highly actionable”

Forward guidance

11 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $3.35B +38.3% YoY
Diluted EPS $1.02 +155% YoY
Net income $752.32M +192.4% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Full-year 2025 revenue grew 36%, EBITDA grew 32%, and normalized FFO per share grew 22.5% to $5.29
  • Q4 normalized FFO per share of $1.45 was up 28.3% year-over-year
  • Q4 SHO same-store NOI grew 20.4%, marking the 13th consecutive quarter above 20%, with SHO organic revenue up 9.6% on 400 bps occupancy gain and 4.7% RevPOR growth
  • Q4 SHO SSNOI margin expanded 270 bps year-over-year
  • Completed $13.9B of Q4 pro rata gross investments, $7.5B of Q4 pro rata dispositions, and $11B of 2025 net investments funded mainly by the $7.2B Outpatient Medical sale with no near-term earnings dilution
  • Closed inaugural private fund (Seniors Housing Fund I) with ~$2.5B of equity commitments and launched Seniors Housing Debt Fund I

Risks & pressure points

  • Q4 reported GAAP net income attributable to common stockholders was only $0.14 per diluted share
  • Outpatient Medical portfolio sale was split across multiple tranches with the remainder set to close in H1 2026, extending execution risk
  • Macro/geopolitical backdrop described as 'fraught with uncertainty,' with long-term interest rates and construction costs remaining 'stubbornly high'
  • Skilled nursing segment faced 'exceptionally challenging' conditions during 2020-2022 from COVID and labor shortages (context cited for the $1.3B SNF disposition)
  • CFO acknowledged labor costs remain a scaling challenge and that non-labor costs like utilities and real estate taxes are headwinds

Key moments

Jump directly to management's words in the synchronized transcript.

“Our organic revenue growth continues to hover around 10%, driven by 400 basis points of year-over-year occupancy gains and healthy rate growth. And as Tim will outline for you shortly, we expect another year of strong occupancy upside in 2026 along with strong pricing power.” Shankh Mitra, CEO
“We ultimately completed nearly $11 billion in net investment activity for the year, consisting primarily of high-growth senior housing properties across all our regions, which were funded in large part through the sale of our outpatient medical business for $7.2 billion.” Shankh Mitra, CEO

Forward guidance

From the 8-K filed Apr 28, 2026.

Metric Guided
Net income attributable to common stockholders
full year 2026
$3.24 – $3.38
Normalized FFO attributable to common stockholders
full year 2026
$6.21 – $6.35
Average blended SSNOI growth
full year 2026
12.25% – 16%
Seniors Housing Operating SSNOI growth
full year 2026
16.5% – 21.5%
Seniors Housing Triple-net SSNOI growth
full year 2026
3% – 4%
Outpatient Medical SSNOI growth
full year 2026
2% – 3%
Long-Term/Post-Acute Care SSNOI growth
full year 2026
2% – 3%
General and administrative expenses
full year 2026
$263M – $271M
Stock-based compensation expense
full year 2026
$60M
Pro rata disposition proceeds
next twelve months
$1.4B

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
FFO per share
full year
$6.28

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Senior Housing Operating$2.79B +49.4% YoY
Triple Net$392.11M +53.8% YoY
Outpatient Medical$71.13M -66.3% YoY

Capital returned

Dividend / share
$0.74
Full-screen source Call document